Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2419-2428
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2419
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2419
Table 1 Comparison of baseline data among groups, mean ± SD or n (%)
Group | Control group | Frailty group | MetS group | Merging group |
N | 125 | 50 | 65 | 50 |
Age (yr) | 66.76 ± 5.16 | 73.30 ± 5.94a | 67.08 ± 4.89 | 68.90 ± 6.33 |
BMI (kg/m2) | 22.88 ± 2.10 | 22.48 ± 2.00 | 25.15 ± 3.15a | 26.33 ± 3.33a |
Female | 7 (28.0) | 4 (40.0) | 4 (30.8) | 5 (50.0) |
Complication | 10 (40.0) | 7 (70.0) | 13 (100.0)a | 9 (90.0)a |
Polypharmacy | 1 (4.0) | 0 (0.0) | 3 (23.1) | 1 (10.0) |
NRS2002 ≥ 3 | 7 (28.0) | 2 (20.0) | 3 (23.1) | 2 (20.0) |
TNM III | 9 (36.0) | 5 (50.0) | 4 (30.8) | 7 (70.0) |
Table 2 Differentially abundant metabolite information between metabolic syndrome group and control group
MS2 | MS2 | Ingredient | VIP | Difference multiple | P value |
Ribothymidine | 0.977184462 | 5-liter urine test | 2.875235598 | 0.853099352 | 0.001 |
LysoPC[20:3(5Z,8Z,11Z)] | 0.431478462 | Glycerophospholipids | 2.617379975 | 1.316226543 | 0.003 |
Sucrose | 0.587560154 | Sucrose | 2.505082856 | 0.294077555 | 0.009 |
2-methylglutaric acid | 0.868639769 | 2-methylglutaric acid | 2.492929728 | 0.880090096 | 0.007 |
PC 22:5(4Z,7Z,10Z,13Z,16Z) | 0.761099923 | Glycerophospholipids | 2.430802959 | 1.197463285 | 0.010 |
PC 22:2(13Z,16Z)/16:1(9Z) | 0.814371846 | Glycerophospholipids | 2.419402577 | 1.372234468 | 0.003 |
Β-alanine | 1.000000000 | β monoalanine | 2.387846925 | 1.191057245 | 0.011 |
Orotidine | 0.755108923 | Orotidine | 2.385776400 | 1.285397754 | 0.004 |
PC[P-18.1(11Z)/14:0] | 0.724108077 | Glycerophospholipids | 2.37334905 | 0.672678582 | 0.009 |
2-benzylbutanediaic acid | 0.671941538 | A-benzylsuccinic acid | 2.309647568 | 0.601709013 | 0.021 |
Table 3 Differentially abundant metabolite information between the frail group and the control group
MS2 | MS2 | Ingredient | VIP | Difference multiple | P value |
Phytosphingosine | 0.454496692 | Phytosphingosine | 3.657534241 | 1.294323976 | 4.96942 × 10-5 |
Ethylbenzene | 0.999986538 | Ethyl benzene | 2.933313807 | 0.779138228 | 3.49882 × 10-5 |
Arginyl-Aanin | 0.538666308 | Arginine monoalanine | 2.637262363 | 0.670807534 | 9.32837 × 10-5 |
Beta-D-glucosamine | 0.479228462 | 3-D-glucosamine | 2.523529662 | 1.706788545 | 0.040552211 |
2.3-dimethy1-2-cydohexen-1 | 0.583867615 | Ketones | 2.426992074 | 0.745005971 | 0.003652162 |
N-Acetylvaline | 0.523245077 | N-acetyl-DL-valine | 2.425756767 | 0.548096577 | 6.01189 × 10-5 |
Alpha-dimorphecolic acid | 0.979338000 | Fatty acids | 2.422824991 | 0.591828042 | 0.01624548 |
Arachidonic acid | 0.626860308 | Arachidonic acid | 2.41783857 | 1.448871331 | 0.006223154 |
D-citrulline | 0.996183538 | D-citrulline | 2.354091235 | 0.738050459 | 0.014028588 |
Succinic acid semialdehyde | 0.973268385 | Succinic acid | 2.310730757 | 1.414979613 | 0.045517081 |
Table 4 Differentially abundant metabolite information between the merged group and the control group
MS2 | MS2 | Ingredient | VIP | Difference multiple | P value |
2-aminoacetophenone | 1.000000000 | Aromatic compounds | 2.961804513 | 2.196907422 | 0.015884556 |
Alpha-N-phenylacetyl | 0.999461308 | A-N-phenylacetyl | 2.922737465 | 2.928594266 | 0.015713599 |
Arginyl-alaninr | 0.538666308 | Argininylalanine | 2.870719541 | 0.577806767 | 0.000093284 |
Pseudouridine | 0.761171308 | pseudouridine | 2.654758398 | 1.209468419 | 0.010376873 |
N-methylnicotinamide | 0.695534769 | N-methylnicotinamide | 2.596565350 | 0.436187388 | 0.023415222 |
Dopamine 3-O | 0.583639154 | Dopamine 3-O-monosulfate | 2.508348482 | 1.474559460 | 0.045180328 |
Choline | 1.000000000 | Choline | 2.485758030 | 0.874659513 | 0.004134701 |
N4-acetylcytidine | 0.990193846 | N-acetylcytosine nucleoside | 2.485751726 | 1.458921122 | 0.001565543 |
N-acetyl-L-alanine | 0.907531231 | N-acetyl-L-alanine | 2.462896266 | 1.145011518 | 0.020139388 |
Bliverdin | 0.981282462 | Biliverdin | 2.445197302 | 0.489904504 | 0.003203639 |
Table 5 Key metabolic pathways and metabolites in each group
Group | Route | Hits | Impact | P value |
MetS group | Fructose and mannose metabolism | Sorbitol, mannitol | 0.00887 | 0.0076735 |
Galactose metabolism | Sorbitol | 0.000.00 | 0.113450.0 | |
Metabolism of glyoxylates and dicarboxylates | Glycollic acid | 0.00686 | 0.1368100 | |
Arachidonic acid metabolism | Arachidonic acid | 0.21669 | 0.1671500 | |
Frailty group | Metabolism of alanine, aspartic acid, and glutamic acid | L-aspartic acid and succinic acid semialdehyde | 0.10256 | 0.0069520 |
Vitamin B metabolism | Pyridomide, succinic acid semialdehyde | 0.00000 | 0.0121920 | |
Biotin metabolism | Biotin | 0.20325 | 0.0579490 | |
Metabolism of methyl butyrate | Succinic acid semialdehyde | 0.03343 | 0.1962000 | |
Arachidonic acid metabolic pathway | Succinic acid semialdehyde | 0.21669 | 0.2883000 | |
Merging group | Glycerophospholipid metabolism | Choline, ethanolamine phosphate, glycerophosphatidylcholine | 0.10234 | 0.0037066 |
Sphingolipid metabolism | Plant sphingosine and ethanolamine phosphate | 0.01288 | 0.0175530 | |
Glutathione metabolism | Glutathione | 0.23743 | 0.2735200 | |
Starch and sucrose metabolism | Trehalose | 0.00944 | 0.3439500 | |
Porphyrin and chlorophyll metabolism | Biliverdin | 0.01844 | 0.5880900 |
- Citation: Zhang H, Shen WB, Chen L. Analysis of metabolic characteristics of metabolic syndrome in elderly patients with gastric cancer by non-targeted metabolomics. World J Gastrointest Oncol 2024; 16(6): 2419-2428
- URL: https://www.wjgnet.com/1948-5204/full/v16/i6/2419.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i6.2419